Physician profile
Lori A Brown
NPI 1023520830
$1,333.24
in general payments reported to CMS, 2019-2025
15 companies · $79.42 in 2025
The $79.42 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $480 · 2023: $193 · 2024: $117 · 2025: $79.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $420.34 | 2021-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $164.24 | 2021-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.87 | 2021-2023 | Jardiance, Synjardy |
| Abbott Laboratories | $123.98 | 2021-2022 | |
| Astellas Pharma US INC | $105.60 | 2021-2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $75.52 | 2021 | |
| Pfizer INC. | $57.22 | 2021-2023 | |
| Novo Nordisk INC | $50.12 | 2021-2024 | Saxenda, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $43.16 | 2023-2024 | Trintellix |
| Glaxosmithkline, LLC. | $34.42 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $33.78 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $23.09 | 2025 | |
| Amgen INC. | $17.35 | 2024 | Repatha, Otezla |
| Abbvie INC. | $15.87 | 2021 | |
| Eisai INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.